A consortium of investors led a $250m round in Kardium.

A consortium of investors including Janus Henderson Investors, QIA, MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management and Eckuity Capital, led a $250m round in Kardium, a developer of medical device for the diagnosis and treatment of atrial fibrillation, with participation from T. Rowe Price and Durable Capital Partners. “We’re thrilled to have secured this transformational financing with a world-class syndicate of investors. This funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation,” Kevin Chaplin, Kardium CEO.